title: CD7 expression does not predict for poor outcome in acute myeloblastic leukemia.
authors.forename: Y
authors.initials: Y
authors.lastname: Pillay
authors.forename: G
authors.initials: G
authors.lastname: McLellan
authors.forename: G
authors.initials: G
authors.lastname: Davison
authors.forename: S
authors.initials: S
authors.lastname: Kelly
authors.forename: P
authors.initials: P
authors.lastname: Jacobs
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte; D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin